The Lancet Gastroenterology & Hepatology in conversation with

Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer


Listen Later

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

Follow us today at...

https://bsky.app/profile/lancetgastrohep.bsky.social

https://www.linkedin.com/company/langastro/

https://instagram.com/thelancetgroup

https://facebook.com/thelancetmedicaljournal

https://youtube.com/thelancettv

...more
View all episodesView all episodes
Download on the App Store

The Lancet Gastroenterology & Hepatology in conversation withBy The Lancet Group


More shows like The Lancet Gastroenterology & Hepatology in conversation with

View all
Stuff You Should Know by iHeartPodcasts

Stuff You Should Know

78,484 Listeners

JAMA Editors' Summary by JAMA Network

JAMA Editors' Summary

142 Listeners

Behind The Knife: The Surgery Podcast by Behind The Knife: The Surgery Podcast

Behind The Knife: The Surgery Podcast

1,311 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,373 Listeners

JAMA Medical News by JAMA Network

JAMA Medical News

94 Listeners

The Clinical Problem Solvers by The Clinical Problem Solvers

The Clinical Problem Solvers

517 Listeners

Run the List by Walker Redd, Emily Gutowski, Navin Kumar, Joyce Zhou, Blake Smith

Run the List

252 Listeners

The Lancet Voice by The Lancet Group

The Lancet Voice

20 Listeners

The Lancet Child & Adolescent Health in conversation with by The Lancet Group

The Lancet Child & Adolescent Health in conversation with

0 Listeners

The Lancet Digital Health in conversation with by The Lancet Group

The Lancet Digital Health in conversation with

0 Listeners

The Lancet Global Health in conversation with by The Lancet Group

The Lancet Global Health in conversation with

2 Listeners

The Lancet Oncology in conversation with by The Lancet Group

The Lancet Oncology in conversation with

1 Listeners

The Lancet Psychiatry in conversation with by The Lancet Group

The Lancet Psychiatry in conversation with

0 Listeners

The Lancet Respiratory Medicine in conversation with by The Lancet Group

The Lancet Respiratory Medicine in conversation with

1 Listeners

The Lancet in conversation with by The Lancet Group

The Lancet in conversation with

0 Listeners

The Lancet Haematology in conversation with by The Lancet Group

The Lancet Haematology in conversation with

0 Listeners

The Lancet Diabetes & Endocrinology in conversation with by The Lancet Group

The Lancet Diabetes & Endocrinology in conversation with

1 Listeners

The Lancet Infectious Diseases in conversation with by The Lancet Group

The Lancet Infectious Diseases in conversation with

0 Listeners

The Lancet Public Health in conversation with by The Lancet Group

The Lancet Public Health in conversation with

1 Listeners

The Lancet Microbe in conversation with by The Lancet Group

The Lancet Microbe in conversation with

0 Listeners

eBioMedicine in conversation with by The Lancet Group

eBioMedicine in conversation with

0 Listeners

In conversation with... by The Lancet Neurology

In conversation with...

0 Listeners

The Rest Is Entertainment by Goalhanger

The Rest Is Entertainment

952 Listeners

The Lancet Rheumatology in conversation with by The Lancet Group

The Lancet Rheumatology in conversation with

0 Listeners

The Lancet Regional Health in conversation with by The Lancet Group

The Lancet Regional Health in conversation with

0 Listeners

The Lancet Primary Care in conversation with by The Lancet Group

The Lancet Primary Care in conversation with

0 Listeners

The Lancet Regional Health Americas in conversation with by The Lancet Group

The Lancet Regional Health Americas in conversation with

0 Listeners